Case Study: Leading Biotechnology Company achieves global recruitment and regulatory compliance in a rare neuromuscular Phase III trial with Advarra's Longboat Platform

Ensuring Recruitment and Compliance Success of an Evolving Rare Neuromuscular Disease Study

Leading Biotechnology Company ran a global Phase III (with planned expansion) study of a rare neuromuscular disease across 30 sites in 12 countries over three years. Rapid disease progression and frequent protocol amendments made timely training, consistent compliance, and strong participant/caregiver support critical, so the sponsor selected Advarra’s Longboat Platform for 21 CFR Part 11‑compliant training, recruitment, and patient engagement services.

Advarra deployed the Longboat Platform—providing compliant online training, multilingual recruitment websites, a patient engagement portal, and active project management—which enabled seamless amendment rollouts and higher site engagement. Outcomes included 15 of 30 sites delivering 91% of recruits (and 86% of platform use), over 1,000 mandatory task completions by site staff, 400+ patient/caregiver portal sessions, and a 70% spike in portal usage when Advarra’s team provided direct CRA support, demonstrating improved recruitment, compliance, and participant engagement.